Quick Answer
Karyopharm Therapeutics Inc. reported Net Income of -$196.04 million for fiscal year 2025.
Karyopharm Therapeutics Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$196.04M | -156.5% |
| 2024 | -$76.42M | +46.6% |
| 2023 | -$143.10M | +13.4% |
| 2022 | -$165.29M | -33.2% |
| 2021 | -$124.09M | +36.8% |
| 2020 | -$196.27M | +1.7% |
| 2019 | -$199.59M | -11.9% |
| 2018 | -$178.41M | -38.3% |
| 2017 | -$128.98M | -17.7% |
| 2016 | -$109.58M | +7.3% |
| 2015 | -$118.18M | -56.0% |
| 2014 | -$75.78M | -123.2% |
| 2013 | -$33.95M | -113.7% |
| 2012 | -$15.89M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$33.13M | -3.3% | +11.1% |
| June 30, 2025 | -$37.25M | -256.6% | -58.8% |
| March 31, 2025 | -$23.46M | +37.2% | +26.8% |
| September 30, 2024 | -$32.07M | +7.1% | -234.8% |
| June 30, 2024 | $23.79M | +172.9% | +163.7% |
| March 31, 2024 | -$37.36M | -9.5% | -8.3% |
| September 30, 2023 | -$34.51M | +5.0% | -5.7% |
| June 30, 2023 | -$32.63M | +33.5% | +4.4% |
- Karyopharm Therapeutics Inc. showed a decrease of -156.5% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Karyopharm Therapeutics Inc.’s net income has declined by 1133.9% (from -$15.89 million to -$196.04 million).
- The most recent figure is from Karyopharm Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: